Loretta Vileikyte, MD, PhD Nonostante il suo impatto negativo sulla qualità della vita (QoL), la neuropatia periferica diabetica (DPN) rimane sottotrattata, con solo la metà degli individui che riceve un…
HFX™ for PDN Now the Only Spinal Cord Stimulation System Approved by FDA to Treat PDN¹ Company Will Immediately Initiate Commercial Launch Activities in the U.S. Company Announces Preliminary, Unaudited…
SENZA-PDN Study is Largest Prospective, Multicenter, Randomized Clinical Trial of Spinal Cord Stimulation Conducted to Date REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that…
Peripheral neuropathy (PN) is associated with mortality, even among individuals without diabetes, according to a study published online Dec. 8 in the Annals of Internal Medicine. Caitlin W. Hicks, M.D.,…